o2h Ventures portfolio company Small Pharma Successfully Completes Phase I Clinical Trial of DMT-assisted therapy
- On September 22, 2021
- By GrowthInvest Marketing
Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers Dataset generated from Phase I enables the selection of the optimal dose of SPL026 to take forward into Phase IIa Small Pharma’s Phase IIa clinical trial to explore the effectiveness of SPL026 in combination with psychotherapy for the treatment of Major Depressive Disorder has been initiated.
GET IN TOUCH!
CALL US020 7071 3945
FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.